Selected 3rd-quarter drug sales for Merck & Co.

AP News
|
Posted: Oct 28, 2011 2:33 PM
Selected 3rd-quarter drug sales for Merck & Co.

Here are sales figures for the third quarter for top-selling Merck & Co. prescription drugs:

PRODUCT NAME CONDITION/USE 3Q 2011 SALES 3Q 2010 SALES PERCENT CHANGE

Singulair Asthma/allergies $1.34 billion $1.22 billion up 10 percent

Januvia and Janumet Diabetes $1.2 billion $847 million up 41 percent

Remicade Rheumatoid arthritis $561 million $661 million down 15 percent

Zetia High cholesterol $614 million $571 million up 8 percent

Vytorin High cholesterol $469 million $485 million down 3 percent

Cozaar and Hyzaar High blood pressure $404 million $423 million down 4 percent

Isentress HIV treatment $343 million $278 million up 23 percent

Nasonex Allergies $266 million $259 million down 3 percent

Temodar Brain cancer $223 million $254 million down 12 percent

Gardasil HPV vaccine $445 million $316 million up 41 percent

___

Source: Merck & Co.